Yolk-sac tumors account for about 20% of ovarian germ cell tumors and occur predominantly in women below 35 years of age. Modern evidence-based treatment strategies have ensured long term post-treatment survival, but with increased survival, attention has been turned to an urgent need for developing fertility sparing treatment strategies. In this report we describe the successful treatment of a young woman who was able to conceive and deliver two children, in spite of the loss of one ovary two years prior to being diagnosed with an ovarian yolk-sac tumor on the remaining ovary.
The use of molecular markers in sarcomas has been primarily for diagnosis, but increasingly they are also used for prognosis and prediction of response to specific therapies. This article presents 3 case reports of sarcomas to illustrate molecular markers for prognosis/predictive purposes. The prototypical example is gastrointestinal stromal tumor, in which the response to imatinib mesylate therapy is predicted by analysis for KIT mutation. In synovial sarcomas, the type of fusion transcript correlates with the clinical course, with SST-SSX2 having better metastasis-free survival than SYT-SSX1. p53 Mutation is an important prognostic factor in multiple tumors, including Ewing sarcoma. Many studies are ongoing, and molecular analysis will become increasingly important in the treatment of sarcomas.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.